Profile of neratinib and its potential in the treatment of breast cancer
Katharina Feldinger,1 Anthony Kong,2 1Department of Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, 2The Robert Aitkin Institute, School of Cancer Sciences, University of Birmingham, Birmingham, UK Abstract: The HER (ErbB) receptor tyrosine kinase receptors a...
Guardado en:
Autores principales: | Feldinger K, Kong A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5cb301d1dbae4fba992557e02098628a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021) -
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
por: Criscitiello C, et al.
Publicado: (2018) -
Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
por: Saksena R, et al.
Publicado: (2013) -
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
por: Cadoo KA, et al.
Publicado: (2014) -
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
por: Stasi I, et al.
Publicado: (2014)